The 33 references in paper A. Isaykin I., A. Kavelina V., N. Yakhno N., T. Fateeva G., T. Shmidt E., А. Исайкин И., А. Кавелина В., Н. Яхно Н., Т. Фатеева Г., Т. Шмидт Е. (2015) “ОПТИКОМИЕЛИТ // NEUROMYELITIS OPTICA” / spz:neicon:nevro:y:2014:i:5:p:43-51

1
Miyazawa I., fujihara K., Itoyama y. eugene Devic (1858–1930). J. Neurol. 2002; 3: 352–2.
(check this in PDF content)
2
bukhari w., barnett M., Prain K., broadley S. Molecular pathogenesis of neuromyelitis optica. Int. J. Mol. Sci. 2012 (10): 12970– 93.
(check this in PDF content)
3
Paul f., Jarius S., Aktas o. et al. Antibody to aquaporin-4 in the diagnosis of neuromyelitis optica. PLoS Med. 2007; 4: 0669–73.
(check this in PDF content)
4
w ingerchuk D., Lennon V., Pittock S. et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66: 1485–9.
(check this in PDF content)
5
w einshenker b. Devic, neuromyelitis optica: what is it, what it is not and why it is hard to be sure. MSJ. 2012; 18 (Suppl. 4): 52.
(check this in PDF content)
6
Awad A., Stüve o. Idiopathic transverse myelitis and neuromyelitis optica: Clinical profile, pathophysiology and therapeutic choices. Curr. Neuropharmacol. 2011; 9(3): 417–28.
(check this in PDF content)
7
Poppe A., Lapierre y., Melanc D. et al. Neuromyelitis optica with hypothalamic involvement. MSJ. 2005; 11: 617–21.
(check this in PDF content)
8
Vendrame M., Azizi S. A case of NMo with extensive brain stem involvement. Neurol. Res. 2007; 29: 32–5.
(check this in PDF content)
9
Мозолевский Ю.В., Шмидт Т.Е., Яхно Н.Н. и др. Оптикомиелит Девика. Неврологический журнал. 2008; 13(2): 27–32.
(check this in PDF content)
10
Qian P., Lancia S., Alvarez e. et al. Association of neuromyelitis optica with severe and intractable pain. Arch. Neurol. 2012; 69: 1482–7.
(check this in PDF content)
11
Kremer L., Mealy M., Jacob A. et al. brainstem manifestation in neuromyelitis optica. MSJ. 2012; 18 (Suppl. 4): 292.
(check this in PDF content)
12
Asgari N., Skejoe H., Lillevang S. et al. Modification of longitudinally extensive transverse myelitis and brainstem lesions in the case of NMo. BMC Neurol. 2013; 13: 33.
(check this in PDF content)
13
Chezzi A., bergamaschi R., Martinalli V. et al. Clinical characиз работ показано, что у 21% серонегативных по аквапорину-4 пациентов обнаруживаются АТ к МОГ, чего не наблюдалось ни у одного серопозитивного больного и ни в одном случае у больных с РС. Замечено, что среди пациентов с АТ к МОГ преобладают мужчины, в большей степени, чем спинной мозг, страдают зрительные нервы, ОМ чаще имеет монофазное течение, очаги в спинном мозге располагаются каудальнее и происходит лучшее восстановление [28]. При наличии АТ к аквапорину-4 пациенты лучше отвечают на терапию, направленную на подавление В-лимфоцитов, – ритуксимаб (см. ниже). Однако и сегодня продолжаются дебаты о том, действительно ли наличие АТ к аквапорину-4 позволяет дифференцировать ОМ и РС, так как у серонегативных пац
(check this in PDF content)
14
Luppe S., Harding K., Pickersgill T., Robertson N. Visual and motor disability in a cohort of patients with neuromyelitis optica. MSJ. 2012; 18 (Suppl. 4): 68.
(check this in PDF content)
15
Schneider e., Zimmermann H., oberwahrenbrock T. et al. Differences in optica neuritis related retinal damage between patients with neuromyelitis optica and multiple sclerosis. MSJ. 2012; 8 (Suppl. 4): 69.
(check this in PDF content)
16
Palmi-Cortes I., Meca-Lallana V., Canetti b. et al. Recurrent optic neuritis: the importance of the differencial diagnosis. MSJ. 2012; 18 (Suppl. 4): 72.
(check this in PDF content)
17
Mendelevich e.g., bogdanov e.I., Mikhailov I.M., Selezneva A.V. Secondary Syringomyelia in demyelinating diseases. Neurologicheskiy zhuurnal. 2004; 2: 17–21. (in Russian)
(check this in PDF content)
18
Seze J., Stojkovic y., ferriby D. et al. Devic’s neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J. Neurol. 200; 197: 57–61.
(check this in PDF content)
19
Trebst C., Raab P., Voss e. et al. Longitudinally extensive transverse myelitis – it is not all neuromyelitis optica. Nat. Rev.Neurol.
(check this in PDF content)
20
1; 7: 688–98. 20. Matthews L., Marasco R., Jenkinson M. et al. Neuromyelitis optica spectrum disorder and multiple sclerosis can be distinguished on the basis of MRI brain lesion characteristics. MSJ. 2012; 18 (Suppl. 4): 9.
(check this in PDF content)
21
Ringelstein M., Metz I., Ruprecht K. et al. Diagnostic biopsy of spinal tumors: need for prior aquaporin-4 antibody testing. MSJ. 2012; 18 (Suppl. 4): 69.
(check this in PDF content)
22
Kister I., Howard J., Perumal J., Herbert J. brain MRI in a series of NMo-Igg seropositive patients. MSJ. 2012; 18 (Suppl. 4): 8.
(check this in PDF content)
23
Kister I., Herbert J., Zhou y., ge y. Ultra-high-field (7T) MRI of brain lesions ofneuromyelitis optica spectrum disorders and multiple sclerosis. MSJ. 2012; 18 (Suppl. 4): 290.
(check this in PDF content)
24
Marignier R., Nicole A., watrin C. et al. oligodendrocytes are damaged by neuromyelitis optica immunoglobulin g via astrocytes injury. MSJ. 2012; 18 (Suppl. 4): 16.
(check this in PDF content)
25
Misu T., Hoffberger R., fujihara K. et al. Presence of six different lesion types suggest diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol. 2013; (4): 235–41.
(check this in PDF content)
26
Radaelli M., Libera D., Moiola L. et al. Relapsing neuromyelitis optica : clinical characteristics and identification of prognostic factors. MSJ. 2012; 18 (Suppl. 4): 163.
(check this in PDF content)
27
Nytrova P., Horakova D., Kemlink D. et al. The assessment of anti-AQP4 antibody titre as a possible marker of disease activity in patients with neuromyelitis optica. MSJ. 2012; 18 (Suppl. 4): 571.
(check this in PDF content)
28
Sato D., Callegaro D., Lana-Peixoto M. et al. Distinction between Mog antibody-positive and AQP4 antibody-positive NMo spectrum disorders. Neurology. 2014; 82: 474–81.
(check this in PDF content)
29
Keegan M., Pineda A., McClelland R. et al. Plasma exchange for severe attacks of CNS demyelination. Neurology. 2002; 58: 143–6.
(check this in PDF content)
30
bakker J., Metz L. Devic,s neuromyelitis optica treated with intravenous gamma globulin. J. Neurol. Sci. 2004; 31: 265–7.
(check this in PDF content)
31
Collogues N., de Seze J. Current and future treatment approaches for neuromyelitis optica. Ther. Adv. Disord. 2011; 4: 111–21.
(check this in PDF content)
32
Cree b., Lamb S., Morgan K. et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005; 64: 1270–2.
(check this in PDF content)
33
Kim S.-H., Kim S.-y., Huh S.-y. et al. outcome of repeated rituximab treatment in 81 patients with neuromyelitis optica spectrum disorders. MSJ. 2012; 18 (Suppl. 4): 294. teristics, course and prognosis of relapsing Devic’s neuromyelitis optica. J. Neurol. 2004; 251: 47–52.
(check this in PDF content)